In-Depth Examination Of 6 Analyst Recommendations For Valneva

Analysts' ratings for Valneva VALN over the last quarter vary from bullish to bearish, as provided by 6 analysts.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Valneva, revealing an average target of $25.5, a high estimate of $26.00, and a low estimate of $23.00. A decline of 1.92% from the prior average price target is evident in the current average.

Investigating Analyst Ratings: An Elaborate Study

An in-depth analysis of recent analyst actions unveils how financial experts perceive Valneva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valneva. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Valneva compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Valneva's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Valneva's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Valneva analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Valneva Better

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Unraveling the Financial Story of Valneva

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Challenges: Valneva's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -5.41%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Valneva's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -65.51% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Valneva's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -14.03%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Valneva's ROA excels beyond industry benchmarks, reaching -5.14%. This signifies efficient management of assets and strong financial health.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.26, caution is advised due to increased financial risk.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.